Novartis Shares Decline After Pelacarsen Heart Drug Trial Failure

Key Facts

1Novartis announced that the late-stage study for its drug pelacarsen missed its primary objective of reducing risks of death, heart attack, and stroke.

In a move that underscores the significant challenges facing the biotechnology sector in developing cardiovascular treatments, Novartis has faced a setback in its clinical research. The company announced that the late-stage study for its drug pelacarsen missed its primary objective of reducing risks of death, heart attack, and stroke. According to reports, the drug failed to show a statistically significant reduction in major adverse cardiovascular events compared to a placebo in the Phase 3 trial.

These disappointing results cast a shadow over the company's future growth prospects in the cardiovascular segment, directly impacting the stock's valuation. Per market data, clinical trial failures for late-stage drugs typically impact market capitalization, although this event has been partially priced in over the last 48 hours. Ionis Pharmaceuticals, as a partner in the drug's development, is also linked to the outcome of this study.

Shares of NVSEF stood at $164.25 (at close September 03, 2026) prior to the full absorption of this news. Looking ahead at the economic calendar, investors are awaiting German inflation data and Manufacturing PMI releases across Europe, which may influence broader market sentiment. Traders will be watching for potential support levels as the market fully adjusts to the loss of this late-stage pipeline candidate.